2021.06.25 I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
2021.06.21 I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board
2021.06.02 I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
2021.05.19 2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody
2021.05.19 2021.5-FierceBiotech: ASCO: I-Mab’s checkpoint inhibitor drug helper uliledlimab sees early promise in Tecentriq cancer combo test
2021.05.19 I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
2021.05.18 I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome